Shots:
- The US FDA has cleared RefleXion X2 with SCINTIX therapy for the treatment of primary & metastatic lung & bone tumors
- X2 platform provides a 20-fold increase in PET sensitivity, increasing detectable biological signal levels for tumor imaging & potentially broadening the population eligible for SCINTIX therapy based on imaging criteria
- Its wide field-of-view PET detector expands coverage from 5 to 20cm, enabling higher image resolution with reduced noise, improved visualization of moving tumors, & support for autonomous SCINTIX therapy delivery over a larger anatomical area
Ref: Businesswire | Image: RefleXion | Press Release
Related News: Saluda Medical Reports CE Mark Approval of EVA Sensing Technology for Personalized Pain Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
